A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of TB006 in Participants with Parkinson's Disease
Latest Information Update: 12 Jan 2026
At a glance
- Drugs TB 006 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors TrueBinding
Most Recent Events
- 12 Dec 2025 Planned End Date changed from 29 Dec 2025 to 1 Mar 2026..
- 12 Dec 2025 Planned primary completion date changed from 29 Dec 2025 to 1 Mar 2026.
- 20 Feb 2025 Status changed from not yet recruiting to recruiting.